BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  CRISPR

  CRISPR Ex Vivo Gene Editing Gets on Target With Caribou’s Hybrid Guides

  While ex vivo genome editing results in highly effective cell therapies, it can lead to off-target effects. Caribou Biosciences has come up with a novel approach for potentially more precise gene editing compared to all-RNA guides.

  October 14, 2024

   · 

  5 min read

   · 

  Greg Slabodkin
• 

  Mergers & acquisitions

  Lundbeck Deepens Neuro, Rare Disease Portfolio With $2.6B Longboard Buy

  Under the deal, the Danish pharma will gain access to Longboard’s 5-HT2C receptor superagonist that is currently in late-stage development for seizures in various developmental and epileptic encephalopathies, including Dravet syndrome.

  October 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Pfizer Wins FDA Nod for Hemophilia Therapy Amid Activist Investor Challenge

  The approval makes Pfizer’s Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to the company, which is currently embroiled in a row with activist investor Starboard Value.

  October 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena

  European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.

  October 14, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  Evonik to Lay Off Additional Employees, Cutting up to 260 in Germany

  Evonik’s latest layoffs are tied to discontinuing production of keto acids in Hanau, Germany, by the end of next year. Earlier this year, news broke the company is also cutting up to 2,000 employees globally by 2026.

  October 14, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Drug shortages

  Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders

  While the regulator conducts another review into the supply of Eli Lilly’s tirzepatide, compounders will be able to continue selling their own remixed versions of the blockbuster drug.

  October 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA Action Alert: Amgen, Camurus, Iterum and Lexicon

  The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT inhibitor for use alongside insulin in type 1 diabetes and chronic kidney disease.

  October 14, 2024

   · 

  4 min read

   · 

  Tristan Manalac
• Press Releases

  89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2024

  October 14, 2024

   · 

  1 min read
• Press Releases

  Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

  October 14, 2024

   · 

  4 min read
• Press Releases

  Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2024

  October 14, 2024

   · 

  1 min read